Across the past 12 months, open-market trades by NeuroSense Therapeutics insiders were all purchases, totaling $200,000.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Alon Ben-Noon | Chief Executive Officer | 226,712 | 0 | 226,712 | 64.5% | 17 Jun, 2026 |
| 2 | Or Eisenberg | Chief Financial Officer | 75,203 | 0 | 75,203 | 21.4% | 17 Jun, 2026 |
| 3 | Hagit Binder | General Manager | 26,090 | 0 | 26,090 | 7.4% | 30 Mar, 2026 |
| 4 | Niva Russek-Blum | Chief Technology Officer | 23,398 | 0 | 23,398 | 6.7% | 30 Mar, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 16 Jun, 2026 | Or Eisenberg | Chief Financial Officer | Acquired P | 250,000 | $16.00 | $4.00Mn | 75,203 | Direct |
| 16 Jun, 2026 | Alon Ben-Noon | Chief Executive Officer | Acquired P | 250,000 | $16.00 | $4.00Mn | 226,712 | Direct |
| 26 Mar, 2026 | Or Eisenberg | Chief Financial Officer | Acquired A | 200,000 | $0.00 | $0 | 62,703 | Direct |
| 26 Mar, 2026 | Niva Russek-Blum | Chief Technology Officer | Acquired A | 200,000 | $0.00 | $0 | 23,398 | Direct |
| 26 Mar, 2026 | Hagit Binder | General Manager | Acquired A | 200,000 | $0.00 | $0 | 26,090 | Direct |